Commentary: ECMO in the COVID-19 pandemic; when, how and to whom

Won Kyung Pyo, MD, Joon Bum Kim, MD, PhD

PII: S2666-2736(21)00382-X
DOI: https://doi.org/10.1016/j.xjon.2021.10.027
Reference: XJON 407

To appear in: JTCVS Open

Received Date: 20 October 2021
Revised Date: 20 October 2021
Accepted Date: 20 October 2021

Please cite this article as: Pyo WK, Kim JB, Commentary: ECMO in the COVID-19 pandemic; when, how and to whom, JTCVS Open (2021), doi: https://doi.org/10.1016/j.xjon.2021.10.027.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Copyright © 2021 The Authors. Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery
Commentary: ECMO in the COVID-19 pandemic; when, how and to whom

Won Kyung Pyo, MD; Joon Bum Kim, MD, PhD

Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan
College of Medicine, Seoul, Republic of Korea

Word count: 375

Conflict of Interest Statement and Sources of Funding: The authors have nothing to disclose with regard to commercial support

Corresponding author:
Joon Bum Kim, MD, PhD
Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan
College of Medicine
88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea
E-mail: jbkim1975@amc.seoul.kr; Tel: +82-2-3010-5416; Fax: +82-2-3010-6966
Central Message

Further researches regarding to ECMO use may provide answers to its optimal allocation and effective utilization in the COVID-19 pandemic.

Central Picture Legend

Joon Bum Kim, MD, PhD (left), and Won Kyung Pyo, MD (right)
The coronavirus disease 2019 (COVID-19) pandemic has been extended longer than half a year causing millions of deaths. As immunization coverage has increased, the primary goal of medical care converged to treatment of severe patients under the concept of those “with COVID-19.” Extracorporeal membrane oxygenation (ECMO) has played a role as a rescue therapy for people with refractory hypoxemia. Although a large volume of data regarding ECMO use was released from various centers throughout the world, the enormous amount released within a limited time frame or from a small study-sample size with short study period made it difficult to review the effectiveness and indication of ECMO in the COVID-19 surge.1-4

Prolongation of this viral outbreak had led to a critical shortage of resources. Accordingly, use of ECMO, which is a resource-consumptive therapy, was limited. Furthermore, although the effectiveness of ECMO was confirmed during the Middle East respiratory syndrome outbreak and H1N1 pandemic, early reports presented unpromising outcomes of ECMO use, with nearly 90% mortality.5,6 Thus, allocation and effectiveness of ECMO became major concerns.

In the current issue of the Journal, Saeed and Silvestry concisely summarized the history and outcome of ECMO use throughout the COVID-19 pandemic.7 There is no evidence to establish exclusive criteria for ECMO placement because of this severe form of viral pneumonia. However, differentiated guidelines might be contemplated considering the priority issue in resource uses, and the authors well outlined the consensus based on that. In the context of effective allocation of resources restrained, criteria for discontinuation of ECMO also should be pondered, considering the circumstances that candidate patients exceed ECMO resources. Moreover, technical considerations were demonstrated in detail. By including adoption of a novel single dual-lumen right atrial-pulmonary artery device, various
cannulas or strategies were precisely introduced and practically applicable in the field.

Despite the proven efficacy of vaccination and some therapeutic drugs recently introduced, this lethal viral disease will continue to prevail for the time being and there will still be patients with severe respiratory failure. As many countries pose an unprecedented burden on healthcare services, it is important to allow judicious use of resource-intensive treatments such as ECMO. Therefore, further studies pertaining to its outcomes should be allowed to proceed to achieve effective and efficient ECMO use against COVID-19.
Reference


